摘要
目的:探讨西妥昔单抗联合化疗治疗K-Ras野生型转移性结直肠癌(mCRC)的疗效及其影响因素。方法:选取2013年1月~2015年1月河北北方学院附属第一医院收治的K-Ras野生型mCRC患者96例,按照随机数字表法将患者分为对照组(n=48)和观察组(n=48)。对照组给予常规化疗方案治疗,观察组在此基础上给予西妥昔单抗治疗。比较两组临床疗效、中位无进展生存期(PFS)、中位总生存期(OS)以及不良反应发生情况,并分析观察组治疗疗效的影响因素。结果:观察组客观有效率(ORR)和疾病控制率(DCR)分别为54.17%和91.67%,均高于对照组的31.25%和81.25%(P<0.05)。观察组患者中位PFS和中位OS均较对照组长(P<0.05)。观察组皮肤痤疮样病变发生率高于对照组(P<0.05)。单因素分析显示,西妥昔单抗联合化疗治疗K-Ras野生型mCRC的ORR、DCR与年龄、肿瘤部位、肿瘤转移部位、肿瘤分化程度以及西妥昔单抗治疗时间有关(P<0.05)。结论:西妥昔单抗联合化疗治疗K-Ras野生型mCRC疗效确切,预后较好,患者对不良反应可耐受,患者年龄、肿瘤部位、转移部位、分化程度及西妥昔单抗治疗时间可能是其疗效的影响因素。
Objective: To observe the efficacy and influencing factors of cetuximab combined with chemotherapy in the treatment of K-Ras wild-type metastatic colorectal cancer. Methods: 96 patients with K-Ras wild type m CRC who were admitted to First Affiliated Hospital of Hebei North University from January 2013 to January 2015 were selected. The patients were divided into control group(n=48)and observation group(n=48)according to the random number table method. The control group was treated with routine chemotherapy. The observation group was treated with cetuximab on this basis. The clinical efficacy, median progression-free survival(PFS), median overall survival(OS) and adverse reactions were compared between the two groups. The influencing factors of the efficacy of observation group were analyzed. Results: The objective response rate(ORR) and disease control rate(DCR) of the observation group were 54.17% and 91.67% respectively, which were higher than those of the control group 31.25% and 81.25%(P<0.05). The median PFS and OS in the observation group were longer than those in the control group(P<0.05). The incidence of acne-like lesions of skin in the observation group was higher than that in the control group(P<0.05). Univariate analysis showed that the ORR and DCR of cetuximab combined with chemotherapy for K-Ras wild type m CRC were related to age, tumor location, tumor metastasis site, degree of tumor differentiation and treatment time of cetuximab(P<0.05). Conclusion: Cetuximab combined with chemotherapy in the treatment of K-Ras wild type m CRC has definite efficacy and good prognosis. Patients can tolerate adverse reactions. The age, tumor location, metastasis site, differentiation degree and treatment time of cetuximab may be the influencing factors of its efficacy.
作者
孙光源
史玉洁
李文贤
武亮
张月
薛军
SUN Guang-yuan;SHI Yu-jie;LI Wen-xian;WU Liang;ZHANG Yue;XUE Jun(Department of Extracorporeal Vascular Gland Surgery,The First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei,075000,China;Department of Pharmacy,Zhangjiakou First Hospital,Zhangjiakou,Hebei,075000f China;Department of Internal Medicine,Zhangjiakou First Hospital,Zhangjiakou,Hebei,075000,China;Department of Operation Room,The First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei,075000,China)
出处
《现代生物医学进展》
CAS
2019年第18期3563-3567,共5页
Progress in Modern Biomedicine
基金
河北省卫生厅基金项目（201601218）
作者简介
孙光源(1984-),男,硕士研究生,主治医师,研究方向:外科学,E-mail:sun_dr@yeah.net;通讯作者:薛军(1965-),男,硕士研究生,主任医师,研究方向:外科学,E-mail:yfyxuejun@163.com.
